Athenian invested in each of LigoCyte's financing rounds since 2008 and worked closely with LigoCyte's outstanding management team, its employees and our co-investors to advance the company's growth in innovative vaccine products. Takeda, a leading research-based global pharmaceutical company, chose LigoCyte's norovirus vaccine as the first and anchor product candidate of its new Vaccine Business Division. We expect the transaction to yield an excellent return on investment for our limited partners.

Athenian seeks to invest in outstanding companies in healthcare and information technology that impact areas of significant market need. We also look for these superior companies in geographies where other investors may not. Athenian's investment in LigoCyte, based in Bozeman, Montana, is a perfect example of these strategic priorities.

Athenian Venture Partners

Copyright 2012 Athenian Venture Partners | Contact Us